Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 12
1948 23
1949 30
1950 47
1951 49
1952 66
1953 59
1954 70
1955 69
1956 60
1957 98
1958 54
1959 61
1960 52
1961 60
1962 42
1963 59
1964 48
1965 42
1966 65
1967 63
1968 39
1969 52
1970 70
1971 50
1972 105
1973 59
1974 39
1975 42
1976 38
1977 58
1978 71
1979 105
1980 92
1981 87
1982 119
1983 102
1984 94
1985 138
1986 93
1987 155
1988 117
1989 175
1990 222
1991 196
1992 128
1993 117
1994 109
1995 122
1996 110
1997 193
1998 236
1999 329
2000 402
2001 353
2002 383
2003 345
2004 380
2005 477
2006 474
2007 397
2008 449
2009 413
2010 448
2011 449
2012 453
2013 444
2014 430
2015 425
2016 421
2017 468
2018 574
2019 694
2020 501
2021 442
2022 393
2023 488
2024 332

Text availability

Article attribute

Article type

Publication date

Search Results

14,558 results

Results by year

Filters applied: . Clear all
Page 1
Down syndrome and leukemia: from basic mechanisms to clinical advances.
Baruchel A, Bourquin JP, Crispino J, Cuartero S, Hasle H, Hitzler J, Klusmann JH, Izraeli S, Lane AA, Malinge S, Rabin KR, Roberts I, Ryeom S, Tasian SK, Wagenblast E. Baruchel A, et al. Haematologica. 2023 Oct 1;108(10):2570-2581. doi: 10.3324/haematol.2023.283225. Haematologica. 2023. PMID: 37439336 Free PMC article. Review.
Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax.
Rausch J, Dzama MM, Dolgikh N, Stiller HL, Bohl SR, Lahrmann C, Kunz K, Kessler L, Echchannaoui H, Chen CW, Kindler T, Döhner K, Burrows F, Theobald M, Sasca D, Kühn MWM. Rausch J, et al. Haematologica. 2023 Oct 1;108(10):2837-2843. doi: 10.3324/haematol.2022.282160. Haematologica. 2023. PMID: 37102614 Free PMC article. No abstract available.
Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib.
Mesa R, Verstovsek S, Platzbecker U, Gupta V, Lavie D, Giraldo P, Recher C, Kiladjian JJ, Oh ST, Gerds AT, Devos T, Passamonti F, Vannucchi AM, Egyed M, Lech-Maranda E, Pluta A, Nilsson L, Shimoda K, McLornan D, Kawashima J, Klencke B, Huang M, Strouse B, Harrison C. Mesa R, et al. Haematologica. 2024 Feb 1;109(2):676-681. doi: 10.3324/haematol.2023.283106. Haematologica. 2024. PMID: 37259556 Free PMC article. No abstract available.
Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells.
Jia Y, Han L, Ramage CL, Wang Z, Weng CC, Yang L, Colla S, Ma H, Zhang W, Andreeff M, Daver N, Jain N, Pemmaraju N, Bhalla K, Mustjoki S, Zhang P, Zheng G, Zhou D, Zhang Q, Konopleva M. Jia Y, et al. Haematologica. 2023 Oct 1;108(10):2626-2638. doi: 10.3324/haematol.2022.281915. Haematologica. 2023. PMID: 37078252 Free PMC article.
Talquetamab in multiple myeloma.
Liu L, Krishnan A. Liu L, et al. Haematologica. 2024 Mar 1;109(3):718-724. doi: 10.3324/haematol.2023.283931. Haematologica. 2024. PMID: 37855056 Free PMC article.
Worms on stage.
Pandyra AA, Borkhardt A. Pandyra AA, et al. Haematologica. 2023 Dec 1;108(12):3201-3203. doi: 10.3324/haematol.2023.283709. Haematologica. 2023. PMID: 37439330 Free PMC article. No abstract available.
How we manage a high D-dimer.
Franchini M, Focosi D, Pezzo MP, Mannucci PM. Franchini M, et al. Haematologica. 2024 Apr 1;109(4):1035-1045. doi: 10.3324/haematol.2023.283966. Haematologica. 2024. PMID: 37881856 Free PMC article. Review.
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study.
Caimi PF, Ai WZ, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Wang Y, Qin Y, Wang L, Xu ZC, Carlo-Stella C. Caimi PF, et al. Haematologica. 2024 Apr 1;109(4):1184-1193. doi: 10.3324/haematol.2023.283459. Haematologica. 2024. PMID: 37646659 Free PMC article. Clinical Trial.
Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.
Duell J, Abrisqueta P, Andre M, Gaidano G, Gonzales-Barca E, Jurczak W, Kalakonda N, Liberati AM, Maddocks KJ, Menne T, Nagy Z, Tournilhac O, Kuffer C, Bakuli A, Amin A, Gurbanov K, Salles G. Duell J, et al. Haematologica. 2024 Feb 1;109(2):553-566. doi: 10.3324/haematol.2023.283480. Haematologica. 2024. PMID: 37646664 Free PMC article. Clinical Trial.
14,558 results
You have reached the last available page of results. Please see the User Guide for more information.